Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04262466 · ClinicalTrials.gov registry record · Phase 1
Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors
A Phase 1 study of Select Advanced Solid Tumors, sponsored by Immunocore.
- Active
- Registry status
- Phase 1
- Development phase
- 410
- Enrollment target
- 20
- Study locations
NCT04262466: Active Phase 1 study of Select Advanced Solid Tumors, sponsored by Immunocore.
NCT04262466 is a Phase 1 study of Select Advanced Solid Tumors that is active but no longer recruiting, run by Immunocore. The registered enrollment target is 410 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (583% higher). The trial reports 20 study locations across 15 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04262466, a Phase 1 study of Select Advanced Solid Tumors, is active but no longer recruiting, sponsored by Immunocore.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 410 participants
- Enrollment target
- 20
- Study locations
Study Summary
Brenetafusp (IMC-F106C) is an immune-mobilizing monoclonal T cell receptor against cancer (ImmTAC ®) designed for the treatment of cancers positive for the tumor-associated antigen PRAME. This is a first-in-human trial designed to evaluate the safety and efficacy of brenetafusp in adult participants who have the appropriate HLA-A2 tissue marker and whose cancer is positive for PRAME.
Conditions Studied
Interventions
- DRUG Brenetafusp
- DRUG Brenetafusp and pembrolizumab
- DRUG Brenetafusp and chemotherapy
- DRUG Brenetafusp and monoclonal antibodies and chemotherapy
- DRUG Brenetafusp and tebentafusp
Study Locations (20)
California
- University of California - San Diego - La Jolla
- Angeles Clinic and Research Institute - Los Angeles
- University of California Davis Comprehensive Center - Sacramento
Pennsylvania
- Abramson Cancer Center of the University of Pennsylvania - Philadelphia
- Thomas Jefferson University Hospital - Philadelphia
- UPMC Hillman Cancer Center - Pittsburgh
New York
- Columbia University Medical Center - New York
- Memorial Sloan Kettering - New York
Colorado
- University of Colorado - Aurora
District of Columbia
- Georgetown University Medical Center - Washington D.C.
Florida
- Houston Lee Moffitt Cancer Center & Research Institute - Tampa
Illinois
- The University of Chicago Medical Center - Chicago
Iowa
- University of Iowa - Iowa City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 410 participants |
| Start Date | 2020-02-25 |
| Est. Completion | 2027-12 |
| Phase | Phase 1 |
What the registry record for NCT04262466 still lists
NCT04262466 is an interventional study that assigns participants to a tested intervention. The registered 410 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (583% higher).
The record links to 1 condition, with Select Advanced Solid Tumors appearing as the primary indexed condition, and to 5 interventions - of which Brenetafusp is the first listed.
NCT04262466 names 20 study sites across 15 states, led by California, Pennsylvania, New York.
Frequently Asked Questions
What is clinical trial NCT04262466 about?
NCT04262466 is a clinical study titled "Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors". Brenetafusp (IMC-F106C) is an immune-mobilizing monoclonal T cell receptor against cancer (ImmTAC ®) designed for the treatment of cancers positive for the tumor-associated antigen PRAME. This is a first-in-human trial designed to evaluate the safety and efficacy of brenetafusp in adult participants...
What is the current status of trial NCT04262466?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 410 participants. The study started on 2020-02-25. Estimated completion is 2027-12.
What conditions does trial NCT04262466 study?
This clinical trial studies the following conditions: Select Advanced Solid Tumors.
What interventions are being tested in trial NCT04262466?
The interventions under investigation include: Brenetafusp (DRUG), Brenetafusp and pembrolizumab (DRUG), Brenetafusp and chemotherapy (DRUG), Brenetafusp and monoclonal antibodies and chemotherapy (DRUG), Brenetafusp and tebentafusp (DRUG).
Who is sponsoring clinical trial NCT04262466?
This trial is sponsored by Immunocore, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04262466 being conducted?
This trial has 20 study locations across California, Colorado, District of Columbia, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Select Advanced Solid Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04262466's enrollment target sits among peer trials
410 73rd of 2000 higher than 1,927 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Phase 1/2 Study of KSQ-004EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate Genes Encoding SOCS1 and Regnase-1, in Patients With Select Advanced Solid Tumors
RECRUITING · Phase 1
-
First in Human Study of CDR404 in HLA-A*02:01 Participants With MAGE-A4 Expressing Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02043691 · 410 participants · NA
Evaluation of the Cook Custom Aortic Endograft, the Zenith t-Branch Endovascular Graft, and Surgeon-Modified Endograft in Treating Aortic Pathologies
- NCT03042975 · 410 participants
Imaging Genetics of Laryngeal Dystonia
- NCT05730036 · 410 participants · Phase 3
A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma
- NCT05751473 · 410 participants · NA
Reducing Posttraumatic Stress Disorder (PTSD) Symptoms in First Responders and Frontline Health Care Workers
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI